The proton pump inhibitor (PPI) omeprazole decreases the absorption of oral iron by preventing gastric acid secretion, which eliminates the proton gradient required for optimal functioning of the iron transporter. This effect can be clinically significant in patients with iron deficiency anemia. In patients like DL, the indication for the PPI should be critically evaluated, and the PPI discontinued if appropriate. If continued PPI use is required, a longer period of oral iron treatment may be warranted. Patients can also be counseled to take iron supplements on an empty stomach or with a glass of citrus juice. If iron deficiency persists despite these alterations, intravenous iron therapy may be needed to achieve desired outcomes.
The pharmacist should first advise the physician to obtain a thorough cardiovascular history. Fingolimod causes bradycardia with the first dose, which peaks at about 6 hours but can persist for up to 24 hours. The FDA recommends monitoring patients for 6 hours post-dose. Blood pressure and pulse should be measured hourly with electrocardiograms (ECGs) taken before dosing and at the end of observation. In high-risk patients, continuous ECG monitoring should be conducted overnight. High-risk patients include those who are at risk for bradycardia or QT interval prolongation due to medications or preexisting conditions, including ischemic heart disease, myocardial infarction (MI), congestive heart failure, and atrioventricular (AV) block.
Patients who develop a heart rate less that 45 bpm or new onset second degree or higher AV block should be monitored until resolution, and if symptomatic, they should be followed by continuous ECG monitoring until symptoms have resolved. Fingolimod is contraindicated in patients who have experienced the following in the past 6 months: MI, unstable angina, stroke or transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure.
Upon Interview, RG states that she experience an MI 2 years ago. For this reason, she is also being treated with a beta blocker, which can cause bradycardia. RG is a candidate for fingolimod therapy, but she should be considered high risk for cardiovascular adverse events and be monitored overnight with a continuous ECG following her first dose
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs